Skip to main content
. 2017 Jun 13;8:369. doi: 10.3389/fphar.2017.00369

Table 7.

Anakinra and canakinumab (CAN) therapy status after 12 months of follow-up.

ANA CAN
Last Follow-up 32.2 ± 41.5 months 65.75 ± 76.34 months
Ongoing Therapy 49.2% (69/140) patients 50% (1/4) patients
Mean therapy duration 35.7 ± 36.1 months 22.1 ± 16.5 months
Ongoing steroids 31.8% (22/69) patients 100% (3/3) patients
Ongoing DMARDs 50.7% (35/69) patients 33.3% (1/3) patients